RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China)

Structure/Sequence

Molecular FormulaC21H19FN6O2

InChIKeyIIXWYSCJSQVBQM-LLVKDONJSA-N

CAS Registry1454846-35-5

Clinical Trials associated with Lorlatinib

NCT07415005

/ Not yet recruitingPhase 2IIT

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.

Start Date31 Aug 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT07083687

/ Not yet recruitingPhase 2IIT

A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib in TKI na?ve, Advanced ROS1-Positive Non-Small Cell Lung Cancer Patients With Brain Metastases

The goal of this Phase II, multicenter, open-label, single-arm clinical trial is to evaluate the intracranial efficacy and safety of lorlatinib in adults with TKI-na?ve, advanced ROS1-positive non-small cell lung cancer (NSCLC) and untreated brain metastases. The main questions it aims to answer are:
What is the intracranial efficacy (eg., objective response rate/PFS) assessed by revised RECIST v1.1?
How do exploratory biomarkers (e.g., ctDNA dynamics in plasma/CSF) correlate with lorlatinib resistance?
Participants will:
Receive lorlatinib 100 mg orally once daily until disease progression or unacceptable toxicity.
Undergo brain MRI/CT scans every 8 weeks (first 12 cycles) and every 16 weeks thereafter.
Provide blood samples for safety/biomarker analysis and optional CSF samples via lumbar puncture during scheduled visits.

Start Date15 Aug 2025

Sponsor / Collaborator

Hunan Cancer Hospital

NCT06333899

/ Active, not recruitingEarly Phase 1IIT

A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion

The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

Start Date03 Aug 2025

Sponsor / Collaborator

Nationwide Children's Hospital

[+1]

100 Clinical Results associated with Lorlatinib

100 Translational Medicine associated with Lorlatinib

100 Patents (Medical) associated with Lorlatinib

842

Literatures (Medical) associated with Lorlatinib

31 Dec 2026·Lung Cancer Management

Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China

Article

Author: Zhu, Fanfan ; Li, Hongchao ; Xue, Jing ; Le, Hannah ; Duan, Jia ; Hu, Bingqi ; Li, Dingsiman ; Rifi, Nada ; Luan, Luan ; Dong, Peng

AIM:

To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs).

METHODS:

A survey of 105 clinical experts across 23 Chinese regions evaluated healthcare resource utilization (HCRU). Total annual costs with TKIs were calculated by weighting the management costs of patients with and without BM using the cumulative incidence rate (CIR) of BM from ALK-TKI clinical trials.

RESULTS:

First-year management cost averaged ¥24,974 per-patient without BM versus ¥89,859 per-patient with BM, saving ¥64,885. Subsequent years saved ¥33,231. Applying 12-month CIR of BM, the annual costs per-patient were ¥26,791 for 1 L lorlatinib versus ¥46,516 for crizotinib in the intention-to-treat (ITT) population. Subgroup analysis showed annual costs of ¥25,623 per-patient with lorlatinib in those without BM and ¥29,775 in those with BM. Alectinib's and brigatinib's costs were ¥31,073 and ¥32,760 respectively, using the 12-month CIR of BM. Lorlatinib's cost savings increased progressively over 1-4 years. Limited CIR beyond 12 months existed for brigatinib and ensartinib. Results from the Asian group's CIR aligned with global trials.

CONCLUSION:

Due to lower BM CIR, lorlatinib showed higher BM management cost savings compared to crizotinib and alectinib in Chinese 1 L patients.

01 Mar 2026·JTO clinical and research reports

ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report

Article

Author: Offin, Michael ; Yakoub, Mohamed ; Yang, Soo-Ryum ; Drilon, Alexander ; Hsu, Charles ; Eng, Juliana

Background:

ALK fusion-positive NSCLC is driven by a range of fusion partners, most often EML4::ALK. The clinical impact, oncogenicity, and resistance mechanisms of rare, noncanonical ALK fusions remain underexplored. We describe two previously unreported ALK fusion partners in NSCLC and explore the potential mechanisms of resistance in each case, including on-target and bypass mutations, as well as the use of next-generation sequencing (NGS) testing on cerebrospinal fluid (CSF) as a useful tool.

Case Presentation:

We report two patients with metastatic NSCLC harboring novel ZFPM2::ALK and TRIM24::ALK fusions. Both patients achieved marked partial responses to first-line alectinib, confirming the oncogenic and actionable nature of the fusions. The patient with ZFPM2::ALK fusion developed leptomeningeal disease after 27 months; CSF NGS revealed persistent fusion and newly acquired CDKN2A/B deletion. The patient with TRIM24::ALK fusion, following durable responses to alectinib and lorlatinib, relapsed with detection of on-target ALK kinase domain mutations (F1174V, I1171N) and MYC amplification on progression.

Conclusions:

These cases expand the landscape of noncanonical ALK fusions in NSCLC which are responsive to approved ALK TKIs and offer insights into oncogenic and resistance mechanisms. Comprehensive molecular workup, including RNA-based NGS, is essential for detecting rare but actionable ALK rearrangements and optimizing therapeutic strategy. NGS of CSF was a valuable tool for the detection of clinically suspected leptomeningeal disease and disease monitoring.

01 Feb 2026·iScience

Hepatotoxicity of new-generation ALK inhibitors versus crizotinib in patients with non-small cell lung cancer: A systematic review and meta-analysis

Article

Author: Chen, Qi ; Du, Xin ; Zhang, Xiaohong ; Wang, Cen ; Zhong, Xue ; Luo, Xingxian ; Gong, Yiru ; Chen, Jiali ; Li, Lizong ; Liu, Yi ; He, Xu ; Huang, Lin

Hepatotoxicity is a known side effect of ALK inhibitors in non-small cell lung cancer. This meta-analysis assessed the hepatotoxicity risk, measured by elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), for new-generation ALK inhibitors versus crizotinib through eight randomized controlled trials with 2,114 patients. The results suggested that new-generation ALK inhibitors were associated with a significantly reduced risk of all-grade ALT elevation (RR = 0.73, 95% confidence interval [CI] [0.58, 0.92]) and a trend toward reduced risk of grades 3-5 ALT elevation (RR = 0.55, 95% CI [0.29, 1.06]). Alectinib, lorlatinib, and brigatinib are associated with lower risks of hepatotoxicity when compared with crizotinib. New-generation ALK inhibitors improved progression-free survival but not in discontinuation rates. Lorlatinib conferred a greater reduction in any grades AST than second-generation inhibitors compared to crizotinib. Our findings suggest that the selection of the ALK inhibitor should be individualized based on the specific profile of hepatotoxicity and their efficacy.

News (Medical) associated with Lorlatinib

11 Feb 2026

·www.biospace.com

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy study evaluating NXP900’s clinical potential in several molecularly and histologically-defined target tumors, and the combination study of NXP900 with osimertinib in patients with EGFR-mutated non-small cell lung cancer (“NSCLC”) are enrolling patients. In addition, a combination with lorlatinib in ALK-positive NSCLC, is pending commencement. With the potential embedded in the NXP900 Phase 1b program, we expect 2026 to be an exciting year for Nuvectis.” Mr. Bentsur concluded, “We remain focused on operational execution and financial responsibility, and believe that our current cash position can take us through multiple potential NXP900 Phase 1b milestones and well into the second half of 2027.” Full Year 2025 Financial Results Cash and cash equivalents were $31.6 million as of December 31, 2025, compared to $18.5 million as of December 31, 2024. The increase of $13.1 million resulted from the Company's February 2025 public offering and from access to our at-the-market facility, partially offset by operating expenses. The Company's net loss was $26.4 million for the year ended December 31, 2025, compared to $19.0 million for the year ended December 31, 2024, an increase in net loss of $7.4 million. Net loss for the 2025 fiscal year included $6.0 million in non-cash stock-based compensation and one-time license fees associated with milestone achievements of $2.4 million. Research and development expenses, including non-cash and one-time non-recurring expenses, were $18.2 million for the year ended December 31, 2025, compared to $12.9 million for the year ended December 31, 2024, an increase of $5.3 million. General and administrative expenses, including non-cash and one-time non-recurring expenses, were $9.4 million for the year ended December 31, 2025, compared to $6.9 million for the year ended December 31, 2024, an increase of $2.5 million. Finance income was $1.1 million for the year ended December 31, 2025, compared to $0.8 million for the year ended December 31, 2024, an increase of $0.3 million. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's assets include NXP900 a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and the Phase 1b program has been initiated. For more information on Nuvectis, please visit our website at . Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend", "seek", "may", "might", "plan", "potential", "predict", "project", "target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward looking statements are based on Nuvectis Pharma, Inc.'s current expectations and interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for NXP900 and the timing and safety and efficacy data expectations for the monotherapy and combination components of the NXP900 Phase 1b program and estimates and projections regarding our financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in our 2025 Form 10-K and our other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Company Contact Ron Bentsur Chairman, Chief Executive Officer and President rbentsur@nuvectis.com Media Relations Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com NUVECTIS PHARMA, INC. BALANCE SHEETS (USD in thousands, except per share and share amounts) December 31, 2025 2024 Assets CURRENT ASSETS Cash and cash equivalents $ 31,634 $ 18,533 Other current assets 75 74 TOTAL CURRENT ASSETS 31,709 18,607 TOTAL ASSETS $ 31,709 $ 18,607 Liabilities and Shareholders’ Equity CURRENT LIABILITIES Accounts payables $ 6,274 $ 2,498 Accrued liabilities 115 840 Employee compensation and benefits 6,907 5,556 TOTAL CURRENT LIABILITIES 13,296 8,894 TOTAL LIABILITIES 13,296 8,894 COMMITMENTS AND CONTINGENCIES, see Note 3 SHAREHOLDERS’ EQUITY, see Note 6 Common Shares, $0.00001 par value – 60,000,000 shares authorized as of December 31, 2025, and December 31, 2024, 25,676,798, and 19,495,683 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively * * Additional paid in capital 118,100 82,958 Accumulated deficit (99,687 ) (73,245 ) TOTAL SHAREHOLDERS’ EQUITY 18,413 9,713 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 31,709 $ 18,607 * Represent amount lower than $1,000 USD. NUVECTIS PHARMA, INC. STATEMENT OF OPERATIONS (USD in thousands, except per share and share amounts) For the year ended For the year ended December 31, 2025 December 31, 2024 OPERATING EXPENSES Research and development $ 18,153 $ 12,918 General and administrative 9,421 6,929 OPERATING LOSS (27,574 ) (19,847 ) Finance income 1,132 847 NET LOSS $ (26,442 ) $ (19,000 ) EFFECT OF WARRANTS MODIFICATION, (2,429 ) — TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS (28,871 ) (19,000 ) BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING $ (1.32 ) $ (1.11 ) Basic and diluted weighted average number of common shares outstanding 21,812,716 17,113,169

Phase 1Financial Statement

03 Feb 2026

·www.pharmaceutical-technology.com

Pfizer sets sights on R&D strategy amid modest FY25 results

Pfizer and investors alike look forward to further developments within the pharma’s newly acquired obesity portfolio. Image credit: ShU studio via ShutterStock.com. New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company looks to refresh its portfolio amid looming patent losses and waning Covid vaccine sales. In FY25, Pfizer generated full-year revenues of $62.6bn. While this meets the company’s previously adjusted FY25 profit forecast of $62bn , it represents a 2% operational decline compared to FY24. Earnings per share (EPS) were in line with Citi analyst consensus, standing at $1.36, although they were lower than the 2024 rate of $1.41. The company also reaffirmed its 2026 financial guidance, with revenues between $59.5bn and $62.5bn expected, with a diluted EPS range of $2.80 to $3.00. The results follow a tough 2025 for Pfizer, in which the company has battled with declining Covid-19 vaccine sales and the upcoming loss of exclusivity impacting several key drugs in its portfolio, including Janus kinase (JAK) inhibitor, Xeljanz (tofacitinib). Currently, Pfizer forecasts that patent expiries will result in $1.5bn of revenue losses in FY26. Despite this overall loss, 2025 revenues were looking more favourable when Covid-19 vaccines Paxlovid (nirmatrelvir/ritonavir) and Comirnaty (Covid-19 vaccine, mRNA) were discounted from the equation – with the rest of the company’s pipeline achieving operational growth of 6%. Within its wider primary care portfolio, Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo was a strong driver of growth, bringing in $1bn across the global market – up 37% from the $755m in total sales achieved in FY24. This offset the 9% total revenue decline observed in the US, which comes amid the Trump administration’s continued efforts to alter vaccine policy . Sanofi’s RSV jab, Beyfortus (nirsevimab), experienced a similar, but steeper decline in US sales during FY2025 . GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Pfizer and Bristol Myers Squibb’s (BMS) best-selling blood thinner, Eliquis (apixaban), also had a good year, posting an 8% sales increase compared to 2024, with $7.96bn in total sales for 2025. However, this may be one of the last years of consistent growth for the factor Xa blocker, as its key patents are set to expire between 2027 and 2029. Within its oncology portfolio, Pfizer touted positive financial results from its antibody-drug conjugate (ADC) Padcev (enfortumab vedotin), which made 22% more than 2024 by generating global sales of $1.94bn. It was a similar story for anaplastic lymphoma kinase (ALK) inhibitor Lorbrena (lorlatinib), which hit blockbuster status while demonstrating YoY growth of 40%. Despite these wins, investors do not appear to be best pleased with Pfizer’s overall FY25 sales outcome, as the pharma’s stock value dropped by 4.9% from $26.66 at market close on 2 February to $25.36 at market open on 3 February after the results debuted. The New York-based pharma has a market cap of $144.4bn. Pfizer focuses on R&D to foster future growth In an investor call held on 3 February, Pfizer’s CEO, Albert Bourla, touted 2026 as a “key catalyst” for the company’s future growth up to 2030, noting that the initiation of 20 key pivotal studies will help “maximise opportunities” for the company. At the recent 2026 J.P. Morgan Healthcare Conference in San Francisco, Bourla shared Pfizer’s plans to deliver a “catalyst-rich R&D agenda,” while maximising the value of its recent transactions – including its $10bn buyout of obesity biotech, Metsera . This deal already appears to be reaping benefits for Pfizer, as its newly acquired, once-monthly glucagon-like peptide 1 receptor agonist (GLP-1RA), PF3994, met its primary trial endpoint of significant weight reduction at 28 weeks during the Phase IIb VESPER-3 study (NCT06973720). The therapy, which was previously known as MET-097i, is now expected to enter 10 Phase III trials in 2026 across the obesity space. In a research note, Citi analysts noted that they were most compelled by the successful transition to a monthly dosing schedule, as well as the continued weight loss trajectory with no observed plateau, which they say could “reinforce confidence in the asset’s potential”. To help fund studies on its clinical pipeline, Bourla noted that Pfizer has been, and will continue to create cost savings within R&D and across the wider business through the deployment of artificial intelligence (AI). Adding to Bourla’s point, Chris Boshoff, CSO and president of R&D, says the company is “recruiting and embedding AI engineers” across discovery, medical regulatory, safety, pharmacovigilance and clinical trial execution to “measure success, productivity, speed and costs”.

Clinical ResultPhase 2VaccineAcquisitionPhase 1

03 Dec 2025

·firstwordpharma.com

Pfizer, Regeneron back TRIANA's $120M raise to advance lead molecular glue

TRIANA Biomedicines unveiled its lead molecular glue degrader programme on Wednesday, alongside an oversubscribed $120-million series B to push TRI-611 into proof-of-concept testing. Pfizer Ventures returned to participate in the round after backing the biotech's $110-million fundraise in 2022. Last year, the pharma inked a deal with TRIANA worth up to $1.5 billion to discover molecular glue degraders against multiple targets across several disease areas, including oncology (see – Spotlight On: Pfizer takes cautious approach to next protein degrader bet).Wednesday's raise also welcomed a new biopharma backer, Regeneron Pharmaceuticals. The round was co-led by Ascenta Capital and Bessemer Venture Partners, with support from other new investors YK Bioventures, Invus Finchley Healthcare Ventures, as well as existing investors RA Capital Management, Atlas Venture, Lightspeed Venture Partners and Surveyor Capital.Overcoming resistance roadblock CEO Patrick Trojer told FirstWord that TRIANA plans to file an IND with the FDA by year-end to test TRI-611, an ALK-targeted molecular glue degrader, in patients with ALK-positive non–small-cell lung cancer (NSCLC). While ALK tyrosine kinase inhibitors, like Pfizer's Lorbrena (lorlatinib), have helped many individuals with NSCLC, several drugmakers are working on ways to improve ALK-targeting therapies. Last month, Nuvalent got a stock bump after sharing mid-stage data suggesting its ALK inhibitor could be effective in the post-Lorbrena setting."We accelerate our drug discovery efforts with emphasis on known disease-causing protein targets," Trojer said. "The role of ALK tyrosine kinase inhibitors in NSCLC is well established and current therapies have markedly improved outcomes for patients with ALK-positive NSCLC, but acquired resistance and tolerability issues remain as key challenges in treatment of patients." The series B funds will also enable TRIANA to nominate a second therapeutic candidate next year.

PROTACs

100 Deals associated with Lorlatinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11012	Lorlatinib	L01XE44	DB12130

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
ALK positive Non-Small Cell Lung Cancer	United States	Pfizer Inc.	02 Nov 2018
Non-Small Cell Lung Cancer	Japan	Pfizer Inc.	21 Sep 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
metastatic non-small cell lung cancer	Phase 3	United States	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	China	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	Japan	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	Argentina	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	Australia	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	Belgium	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	Canada	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	Czechia	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	France	Pfizer Inc.	11 Jul 2017
metastatic non-small cell lung cancer	Phase 3	Germany	Pfizer Inc.	11 Jul 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ASIA2025	Not Applicable	ALK positive Lung Cancer	70	Crizotinib	klaturfear(papzbvgzci) = fhxksbmmud jnicyuseth (glhajttdar, 34 - 65) View more	Positive	05 Dec 2025
NCT06893354 (LORTAN, ESMO_ASIA2025)	Phase 2	First line \| Neoadjuvant ALK+	20	Lorlatinib	tnadaypnry(cdltufszmo) = frrmnalqjd snuclsgyck (mzvfarblje ) View more	Positive	05 Dec 2025
				Lorlatinib + Chemotherapy	atevgbkbsq(umeqvzgsgd) = vxynbjmlcq xqabcdwueg (tbqfwjgmxn ) View more
NCT07083687 (ESMO_ASIA2025)	Phase 2	Reactive oxygen species 1 positive non-small cell lung cancer First line ROS1-positive	21	Lorlatinib 100 mg QD (advanced ROS1-positive non-small cell lung cancer with brain metastases)	yqdcqroztq(wgwyhulitx) = fllojxatep djzayelnhs (dlxmioaoot )	Positive	05 Dec 2025
NCT03612154 (Pubmed \| JAMA Oncol)	Phase 2	Reactive oxygen species 1 positive non-small cell lung cancer First line ROS1 rearrangement	32	Lorlatinib 100 mg daily	ifkizjrcaw(qhjzfnpciw) = rmqzvbulru ultscbfpxo (ltnxiwhiht, 56 - 86) View more	Positive	26 Nov 2025
				Lorlatinib 100 mg daily (Treatment-naive)	ifkizjrcaw(qhjzfnpciw) = klaojjoyap ultscbfpxo (ltnxiwhiht ) View more
NCT03052608 (CROWN, Pubmed \| Oncologist)	Phase 3	ALK positive Non-Small Cell Lung Cancer	149	Lorlatinib	aywrjjiufd(uodrnlikih) = jhgyuvcpsj tskpcoykmq (yyfpavclmc ) View more	Positive	22 Oct 2025
NCT04621188 (ALBATROS, ESMO2025) Manual	Phase 2	Reactive oxygen species 1 positive non-small cell lung cancer ROS1 Positive	54	Lorlatinib 100 mg/dayLorlatinib 100 mg/day	ebuxsrwvaf \| xmknoyltbb(krhlwhrtfs) = shszigqdbq fvvauslwqc (bucjwyocez ) View more	Positive	17 Oct 2025
NCT03052608 (CROWN, ESMO2025)	Phase 3	ALK positive Non-Small Cell Lung Cancer ALK+	198	Lorlatinib (pts with low methylation-based TF (TF ≤ median))	owenfsdjvf(vuicnrssbu): HR = 0.48 (95.0% CI, 0.26 - 0.9)	Positive	17 Oct 2025
				Lorlatinib (pts with high TF (TF > median))
ESMO2025	Not Applicable	Non-Small Cell Lung Cancer	12,820	Osimertinib	fruorszdcm(wrvibhqqxp) = ayxnnzczfs qxhiawnrep (gtfgzstmpg, 0.7 - 1.4) View more	Positive	17 Oct 2025
				Alectinib	fruorszdcm(wrvibhqqxp) = suvimccupb qxhiawnrep (gtfgzstmpg, 0.2 - 0.6) View more
NCT01970865 \| NCT02737501 \| NCT02075840 \| NCT02604342 \| NCT02094573 \| NCT03052608 (1027 Study EXP2-3A, WCLC2025) Manual	Not Applicable	ALK positive Non-Small Cell Lung Cancer Second line \| First line ALK Positive	-	lorlatinib+alectinib+chemotherapy	ejgmsprodl(chehizprqr) = oeioqusrqi eqkndenlgg (dsnvxybfuz ) View more	Positive	09 Sep 2025
				lorlatinib+brigatinib+chemotherapy	ejgmsprodl(chehizprqr) = mvtdouhssf eqkndenlgg (dsnvxybfuz ) View more
NCT03052608 (CROWN, Pubmed \| J Thorac Oncol) Manual	Phase 3	ALK positive Non-Small Cell Lung Cancer First line ALK Positive	-	Lorlatinib 100 mg	wkkjqnzjea(ilxqtbllky) = zswnjbppcv rutvdigxxa (pevjuxuxxt, 64.3‒NR) View more	Positive	01 Jul 2025
				Crizotinib 250 mg	wkkjqnzjea(ilxqtbllky) = ovdctfitvd rutvdigxxa (pevjuxuxxt, 7.2‒12.7) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis